Different equilibrium dissociation constants for the inhibitors can be set in lines
16–21 of EQ7.m.
The calculated curves shown in Fig. 5.12 are not symmetric. They differ
markedly from symmetric logistic functions (Fig. 3.7) routinely used for the
analysis of dose–response curves [8]. The asymmetric shape is a general feature
of compound binding to multiple sites: At low concen trations, only a small fraction
of the sites is occupied, mostly in the form of singly boun d receptor. For
dose–activity curves this results in relatively low increases of inhibition with the
inhibitor concentration. Multiple bound receptors will only appear at higher inhibi-
tor concentrations, where the concentration of free (active) receptor then rapidly
decreases.
Reaction scheme (5.19) or dose–response curves shown in Fig. 5.12 do not prove
allosteric interactions. The same scheme and the same dose–response curves have
been interpreted isosterically as transient binding patches [9]. We can conclude that
dose–response curves with Hill coefficients larger than one cannot be calculated
from binding equilibria with one inhibitor or activator binding site alone, be it an
allosteric mechanism or not. For our own studies with chitinase inhibition, we had
found Hill coefficients different from one, looked again at our X-ray structures and
identified two inhibitor-binding sites [10]. Whenever Hill coefficients larger than
one are found, there must be reasons for it. Fitting dose–response curves to
plausible reaction schemes should be possible with the programs presented here
or with enhanced modifications. Additional evidence (like isothermal calorimetry
or crystal structure) will help to refine the model and lead to a consistent under-
standing of the mechanisms involved.
References
1. More JJ, Garbow BS, Hillstrom KE (1980) User guide for MINIPACK-1. Argonne National
Laboratory Report ANL-80-74
2. Berger W, Prinz H, Striessnig J, Kang H-C, Haugland R, Glossmann H (1994) Complex
molecular mechanism for dihydropyridine binding to L-type Ca
2+
-channels as revealed by
fluorescence resonance energy transfer. Biochemistry 33:11875–11883
3. http://en.wikipedia.org/wiki/Allosteric_regulation
4. Monod J, Wyman J, Changeux JP (1965) On the nature of allosteric transitions: a plausible
model. J Mol Biol 12:88–118
5. Verhulst PF (1845) Recherches mathe
´
matiques sur la loi d’accroissement de la population.
Nouv me
´
m de l’Academie Royale des Sci et Belles-Lettres de Bruxelles 18:1–41
6. Fenton AW (2008) Allostery: an illustrated definition for the ‘second secret of life’. Trends
Biochem Sci 33:420–425
7. NIH Data base: http://www.ncbi.nlm.nih.gov/sites/entrez. Chem BioAssay
8. Guidelines for standardized dose-response curves: http://www.ncgc.nih.gov/guidance/
manual_toc.html
9. Prinz H, Sch
€
onichen A (2008) Transient binding patches: a plausible concept for drug binding.
J Chem Biol 1:95–104
10. Pantoom S, Vetter IR, Prinz H, Suginta W (2011) Potent family-18 chitinase inhibitors: X-ray
structures, affinities and binding mechanisms. J Biol Chem, 286:24312–24323
70 5 Equilibrium Binding